All currency values in C$ millions unless otherwise noted
Scroll
| Income Statement | TTM | OCT 2025 | OCT 2024 | OCT 2023 | OCT 2022 | OCT 2021 |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenue | C$0 | C$0 | C$0 | C$0 | C$0 | C$0 |
| Operating Income | -C$10 | -C$15 | -C$32 | -C$41 | -C$25 | -C$7 |
| Non-Operating | ||||||
| Net Interest Expense | -C$2 | -C$1 | -C$1 | -C$0 | -C$0 | -C$0 |
| Income Tax Expense | -C$0 | C$0 | C$0 | C$0 | – | – |
| Net Income | ||||||
| Net Income | -C$12 | -C$16 | -C$32 | -C$39 | -C$24 | -C$7 |
| Per Share Data | ||||||
| Revenue Per Share | C$0.00 | C$0.00 | C$0.00 | C$0.00 | C$0.00 | C$0.00 |
| EPS (Basic) | -C$0.04 | -C$0.05 | -C$0.10 | -C$0.13 | -C$0.09 | -C$0.03 |
| EPS (Diluted) | -C$0.04 | -C$0.05 | -C$0.10 | -C$0.13 | -C$0.09 | -C$0.03 |
| Shares Outstanding | 351.1M | 328.3M | 307.0M | 303.3M | 273.6M | 245.5M |
Sernova Biotherapeutics (SVA) financials: revenue, profit and margins
Sernova Biotherapeutics (SVA) generated about C$0.00 in revenue and -C$12 million in net income over the trailing twelve months. Figures are from company filings; this is analysis, not investment advice.
Frequently asked
What is Sernova Biotherapeutics's (SVA) revenue?+
Sernova Biotherapeutics generated about C$0.00 in revenue over the trailing twelve months. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Is Sernova Biotherapeutics profitable?+
Sernova Biotherapeutics reported about -C$12 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
Peers
Biotechnology · Pick stocks to compare with SVA
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing SVA
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.